Inhibition of AChE and BChE are the key enzymes in the breakdown of acetylcholine and butyrylcholine that may be considered as one of the treatment approaches against several neurological disorders such as Alzheimer’s disease, senile dementia, ataxia, and myasthenia gravis. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.